Emilio Hirsch is Professor of Experimental Biology in the Medical School, University of Torino since 2005. He has authored more than 200 scientific publications that received more than 18000 citations. He is an internationally recognized scientist, elected member of the European Molecular Biology Organization (EMBO), Fellow of the International Society of Heart Research (ISHR) and receiver of the American Association for Cancer Research (AACR) innovator prize. He contributed seminal work in the characterization of key signal transduction enzymes named PI3Ks with publications in Science, Nature and Cell. He was involved in the identification of the first PI3K inhibitors for the treatment of cancer and inflammation. His experience in drug discovery was seminal to the design of Kithers KIT2012. He discovered the scaffolding function of PI3Kgamma that led to the design of Kither’s KIT2014.
Alessandra Ghigo is Associate Professor in the Department of Biotechnology in the University of Torino. She has worked on PI3K scaffold function for more than a decade and provided seminal contributions to the understanding of the non-catalytic role of PI3Kgamma in the control of cAMP regulation. She is author of more than 70 publications in highly reputed journals, including Circulation and Molecular Cell. She is an internationally recognized as expert in cAMP regulation, invited speaker in prestigious conferences including the Gordon Conference on Cyclic Nucleotides. She designed KIT2014 and found its action in Cystic Fibrosis. As such she has been regularly invited speaker at the European and at the North American Cystic Fibrosis meetings.
Marco Kevin Malisani is a business and investment executive, with experience as investor and manager of start-up companies in Italy and the UK. He has significant experience in equity investment and business management in Europe and South East Asia.
Alberto Bardelli is Professor of Histology at the Department of Oncological Sciences of the University of Torino. He is author of more than 200 scientific publications in highly reputed journals including Nature, Science and Cancer Cell. He is one of the most highly cited scientists in the University of Torino and a world leader in the field of oncology. He is member of the European Molecular Biology Organization (EMBO), currently president of the European Association for Cancer Research and recipient of numerous prizes and research acknowledgments. His research focused on the genetic characterization of cancer and Prof Bardelli was one of the first to identify the involvement of PI3K genes in human malignancies. He is co-founder of Horizon Discovery, a biotech company listed at the London stock Exchange and of several other successful business endeavours.
Pier Paolo Pandolfi is Director of the Cancer Center & Cancer Research Institute at Beth Israel Deaconess Medical Center, Harvard Medical School in Boston, USA. He is a world leader in oncology and signal transduction, recipient of numerous prestigious prizes and academic acknowledgments and among the most highly cited scientists with Italian roots. He is author of more than 500 publications with a large number of seminal contributions in Nature, Science, Cell. His work focused on the role of the phosphatase PTEN that counteracts the action of PI3Ks and represents one of the most frequently mutated genes in cancer. Besides this particular interest, Pandolfi’s notable contributions go beyond the cancer field and touch metabolism, inflammation and pulmonary diseases.